Form 4: Terns Pharmaceuticals Director Jill M. Quigley Acquires Stock Options in Lieu of Cash Retainer

Director Jill M. Quigley of Terns Pharmaceuticals acquired stock options in lieu of a $40,000 cash retainer for 2025.

Summary

• Jill M. Quigley, a director at Terns Pharmaceuticals, received 10,657 stock options on February 1, 2025.
• These options were granted in place of her $40,000 cash retainer for the year 2025.
• The options have an exercise price of $4.46 per share and expire on January 31, 2035.
• The options vest monthly, with full vesting achieved by January 1, 2026.

Sentiment

Score: 7

Explanation: The document reflects a standard compensation practice, which is generally positive as it aligns director interests with shareholders. There is no indication of any negative sentiment.

Positives

• The director's decision to take stock options instead of cash may indicate confidence in the company's future performance.
• The vesting schedule aligns the director's interests with the long-term success of the company.

Industry Context

This is a standard practice for compensating non-employee directors, aligning their interests with the company's performance. It is common for directors to receive a mix of cash and equity-based compensation.

Comparison to Industry Standards

• Many biotech companies use stock options as part of director compensation packages.
• The vesting schedule of one year is fairly standard for director stock options.
• The exercise price of $4.46 is specific to Terns Pharmaceuticals and would need to be compared to the current share price to assess its value.

Stakeholder Impact

• Shareholders may view this as a positive sign, as it aligns the director's interests with the company's long-term success.
• The director is incentivized to increase the company's value to benefit from the stock options.

Key Dates

Keywords

stock options, director compensation, insider trading, Terns Pharmaceuticals, equity, vesting